Absence of Nuclear p16 Is a Diagnostic and Independent Prognostic Biomarker in Squamous Cell Carcinoma of the Cervix
Authors:
- Saioa MendazaSMSaioa Mendaza
- Joaquín Fernández-IrigoyenJFJoaquín Fernández-Irigoyen
- Enrique SantamaríaEnrique Santamaría
- Tamara ZudaireTZTamara Zudaire
- Rosa GuarchRGRosa Guarch
- David Guerrero-SetasDGDavid Guerrero-Setas
- August VidalAVAugust Vidal
- José Santos-SalasJSJosé Santos-Salas
- Xavier Matias-GuiuXMXavier Matias-Guiu
- Karina AusínKAKarina Ausín
- María José Díaz de CerioMCMaría José Díaz de Cerio
- Esperanza Martín-SánchezEMEsperanza Martín-Sánchez
Open Access
- 19 March 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (6) , 2125
Abstract
The tumor-suppressor protein p16 is paradoxically overexpressed in cervical cancer (CC). Despite its potential as a biomarker, its clinical value and the reasons for its failure in tumor suppression remain unclear. Our purpose was to determine p16 clinical and biological significance in CC. p16 expression pattern was examined by immunohistochemistry in 78 CC cases (high-grade squamous intraepithelial lesions (HSILs) and squamous cell carcinomas of the cervix –SCCCs). CC cell proliferation and invasion were monitored by real-time cell analysis and Transwell® invasion assay, respectively. Cytoplasmic p16 interactors were identified from immunoprecipitated extracts by liquid chromatography-tandem mass spectrometry, and colocalization was confirmed by double-immunofluorescence. We observed that SCCCs showed significantly more cytoplasmic than nuclear p16 expression than HSILs. Importantly, nuclear p16 absence significantly predicted poor outcome in SCCC patients irrespective of other clinical parameters. Moreover, we demonstrated that cytoplasmic p16 interacted with CDK4 and other unreported proteins, such as BANF1, AKAP8 and AGTRAP, which could sequester p16 to avoid nuclear translocation, and then, impair its anti-tumor function. Our results suggest that the absence of nuclear p16 could be a diagnostic biomarker between HSIL and SCCC, and an independent prognostic biomarker in SCCC; and explain why p16 overexpression fails to stop CC growth.Keywords
Funding Information
- Health Department of the Navarre Government (21/11)
- Navarre Breast Cancer Patients’ Association (SARAY) (SARAY)
- Proteored: “Proof of concept project on proteomic research" (ProteoRed-0000029)
- Proteored, PRB3-ISCIII (ISCIII and ERDF) (PT17/0019/009)
- Universidad Pública de Navarra ((predoctoral grant))
- Spanish Ministry of Science, Innovation and Universities (PTA2015-11895-I)
This publication has 47 references indexed in Scilit:
- Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrowCancer Treatment Reviews, 2014
- Epigenetic alterations in preneoplastic and neoplastic lesions of the cervixClinical Epigenetics, 2012
- p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumorsOncogene, 2011
- Effect of Human Papillomavirus on Cell Cycle–Related Proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in Precursor Lesions of Cervical CarcinomaAmerican Journal of Clinical Pathology, 2009
- RSK1 drives p27Kip1phosphorylation at T198 to promote RhoA inhibition and increase cell motilityProceedings of the National Academy of Sciences, 2009
- ARF in the mitochondria: The last frontier?Cell Cycle, 2008
- Proteomic analysis of p16ink4a‐binding proteinsProteomics, 2007
- Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesisLaboratory Investigation, 2007
- The inner nuclear membrane protein Emerin regulates β‐catenin activity by restricting its accumulation in the nucleusThe EMBO Journal, 2006
- A novel partner for D-type cyclins: protein kinase A-anchoring protein AKAP95Biochemical Journal, 2004